

Investing in companies of the future: A unique, well-defined process of investing in biotechnology and life sciences companies.

FUND COMMENTARY


Even though the Nasdaq Biotech Index (^NBI) was up modestly in February at +1.12%, the Next Edge Biotech and Life Sciences Opportunities Fund (the “Fund”) considerably outperformed, benefiting from significant advances in core holdings due to positive clinical, regulatory and commercial developments. The market is now responding favourably to such news and revaluing companies upward accordingly, in stark contrast to selling on such news over the past three years.

Among the best performers were Viking Therapeutics (VKTX) soaring 219% on positive Phase 2 Obesity data. We initiated our position in VKTX below \$11 during the bleakness of early November when babies were being thrown out with the bathwater, and our favourite buying condition, forced selling, prevailed. Other stellar performers included Nektar Therapeutics (NKTR) +31%, Actinium Pharma (ATNM) +59%, CRISPR

Therapeutics (CRSP) +34%, Phantom Pharma (PHAT) +60%, Sangamo Therapeutics (SGMO) +154%, and Medicenna Therapeutics (MDNA.to) +160%.


When the dust settled, the Next Edge Biotech and Life Sciences Opportunities Fund Class A1 Units advanced +18.03% and the Class F1 Units +18.13%. Over the past three months into the new biotech Bull market, the Class A1 Units rose + 35.63% and the Class F1 Units +36.00% vs +14.55% for the Nasdaq Biotech Index (^NBI).

One of the most encouraging anecdotes for contrarians, is this nascent advance hasn’t convinced investors, as they remain on the sideline, either busy chasing the Magnificent 7, or else doubtful, conditioned by the carnage of the biotech bear market that exhausted itself in November. Either way, it has been a muted at best response to a sector back to delivering returns that has been absent for a very long time.



THE TECHNICAL HALLMARK OF A NEW BIOTECH BULL MARKET IS IN PLACE


Every seven years or so Biotech achieves a deeply oversold condition, such that the percent of hundreds of biotech companies above their 200-day moving average declines to the single digits. That last occurred in June 2022. The sector hit a secondary oversold in early November 18-months after the primary low, typical of what unfolds in new biotech bull markets. What has followed in the past is a sustained advance, made more likely by the broad consolidation so far in the opening months of 2024. Our key indicator has corrected from 73% a month ago down to 56% as the sector exhales.



Source: Bloomberg Data; Concept: Next Edge Capital Corp. as of March 18, 2024

COMPOSITION OF NEXT EDGE BIOTECH AND LIFE SCIENCES OPPORTUNITIES FUND

Composition of Fund Holdings as of February 29, 2024



Cash has briefly doubled from 5.2% to 11% as several strongly performing holdings were trimmed. All of that firepower will be redeployed back to work during the March correction. As a result of booking some profits of a few big movers, US weight declined from 84.2% to 79.6%. That will rebound in March. Canadian holdings declined in weight due to cashing out our holding in Medicenna (MDNA.to) after a +160% move and the risk the company uses the rally to tap the financing market.

Source: RBC Investor & Treasury Services Inc., Next Edge Capital Corp.

FUND PERFORMANCE

HISTORICAL PERFORMANCE¹ Class A

	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	YTD
2024	-6.54%	17.97%	-	-	-	-	-	-	-	-	-	-	10.25% ²
2023	8.71%	-6.40%	-6.52%	5.42%	-1.53%	-3.54%	-1.34%	-4.84%	-11.34%	-9.87%	2.19%	22.83%	-10.30%

HISTORICAL PERFORMANCE¹ Class F

	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	YTD
2024	-6.44%	18.08%	-	-	-	-	-	-	-	-	-	-	10.47% ²
2023	8.81%	-6.76%	-7.18%	5.52%	-1.43%	-3.44%	-1.24%	-4.75%	-11.25%	-9.78%	2.29%	22.94%	-10.41%

HISTORICAL PERFORMANCE¹ Class A1

	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	YTD
2024	-6.49%	18.03%	-	-	-	-	-	-	-	-	-	-	10.37% ²
2023	12.40%	-8.18%	-7.37%	5.47%	-1.47%	-3.48%	-1.28%	-4.78%	-11.29%	-9.82%	2.25%	22.89%	-9.41%
2022	-10.43%	-1.52%	-2.72%	-15.24%	-5.97%	-0.04%	5.56%	2.44%	1.60%	-2.68%	-2.65%	-10.14%	-36.06%
2021	21.23%	0.97%	-4.14%	-4.14%	-6.83%	4.63%	-8.50%	5.77%	-2.86%	-4.37%	-8.13%	-5.93%	-14.80%
2020	-	-	-	-	-	-	-	-	-	-	-	4.39%*	4.39% ²

HISTORICAL PERFORMANCE¹ Class F1

	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	YTD
2024	-6.40%	18.13%	-	-	-	-	-	-	-	-	-	-	10.57% ²
2023	12.50%	-8.11%	-7.28%	5.55%	-1.38%	-3.40%	-1.19%	-4.70%	-11.21%	-9.73%	2.34%	22.99%	-8.42%
2022	-10.35%	-1.44%	-2.63%	-15.17%	-5.84%	0.04%	5.65%	2.54%	1.69%	-2.59%	-2.65%	-9.88%	-35.27%
2021	20.63%	1.62%	-4.05%	-4.05%	-6.74%	4.73%	-8.42%	5.87%	-2.78%	-4.28%	-8.04%	-5.85%	-13.89%
2020	-	-	-	-	-	-	-	-	-	-	-	4.44%*	4.44% ²

IMPORTANT NOTES

1. Next Edge Biotech and Life Sciences Opportunities Fund returns are net of all fees and expenses associated with Class A1 Units and Class F1 Units charged from December 21, 2020 (trading start date). Next Edge Biotech and Life Sciences Opportunities Fund returns are net of all fees and expenses associated with Class A Units and Class F Units charged from January 3, 2023 (trading start date). Returns for 2023 are unaudited. Therefore, performance statistics containing 2023 figures shown in this material are subject to final confirmation. The historical annualized rates of return for the Next Edge Biotech and Life Sciences Opportunities Fund Class A Units as of February 29, 2024 are 1 yr -2.81%, 3 yr N/A, 5 yr N/A, 10 yr N/A, and CARR -0.81%; for Class F Units are 1 yr -2.46%, 3 yr N/A, 5 yr N/A, 10 yr N/A, and CARR -0.76%; for Class A1 Units are 1 yr -3.11%, 3 yr -23.60%, 5 yr N/A, 10 yr N/A, and CARR -16.21%; for Class F1 Units are 1 yr -2.05%, 3 yr -22.73%, 5 yr N/A, 10 yr N/A, and CARR -15.26%.

2. Part Year

* Part Month start date December 21, 2020 to December 31, 2020.

The “Next Edge Biotech and Life Sciences Opportunities Fund” or “Fund” means the “Next Edge Biotech and Life Sciences Opportunities Fund”. Capitalized terms not defined in this report are defined as set forth in the prospectus of the Fund (the “Prospectus”). This communication is not, and under no circumstances is to be construed as, an invitation to make an investment in the Fund nor does it constitute a public offering to sell the Fund or any other products described herein. Applications for the Fund will only be considered on the terms of the Prospectus. Each purchaser of the units (the “Units”) may have statutory or contractual rights of action under certain circumstances as disclosed in the Prospectus. Please review the provisions of the applicable securities legislation for particulars of these rights.

Potential investors should note that alternative investments can involve significant risks and the value of an investment may go down as well as up. There is no guarantee of trading performance and past or projected performance is not indicative of future results. Investors should review the Prospectus in its entirety for a complete description of the Fund, its risks, and consult their registered dealers before making an investment.

Any descriptions or information involving investment process or strategies is provided for illustration purposes only, may not be fully indicative of any present or future investments, may be changed at the discretion of the Portfolio Manager and are not intended to reflect performance. The following does not purport to be a complete summary of all of the risks associated with an investment in the Fund. Please see the Fund’s Prospectus for a complete listing and description of the risks associated with an investment in the Fund. The Fund is generally exposed to the following risks: Biotechnology Industry Risk; Borrowing Risk; Counterparty Risk; Credit Risk; Cybersecurity Risk; Derivatives Risk; Equity Securities Risk; ETF Risk; Foreign Currency Risk; Foreign Securities Risk; Interest Rate Risk; Legislation and Litigation Risk; Leverage Risk; Liquidity Risk; Multiple Class Risk; Options Risk; Price Volatility Risk; Repurchase and Reverse Repurchase Transactions and Securities Lending Risk; Short Selling Risk; Stock Market Risk; Substantial Securityholder Risk and Tax Risk.

The Fund is not a trust company and does not carry on business as a trust company and, accordingly, the Fund is not registered under the trust company legislation of any jurisdiction. Units of the Fund are not “deposits” within the meaning of the Canada Deposit Insurance Corporation Act (Canada) are not insured under provisions of that Act or any other legislation.

The information provided herein is for information purposes only and does not constitute a solicitation, public offering, advice or recommendations to buy or sell interests in the Fund, the Portfolio, Units or any other Next Edge Product. Please refer to the Fund’s prospectus for more information on the Fund as any information in this Report is qualified in its entirety by the disclosure therein.

The information contained in this material is subject to change without notice and Next Edge Capital Corp. will not be held liable for any inaccuracies or misprints. The Fund has not been and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States. The Fund may not be offered or sold in the United States or to US persons.

Opinions expressed are those of the author as of the date of this report, are subject to change and may not reflect the opinion of all members of the Company. Some statements contained in this material concerning goals, strategies, outlook or other non-historical matters may be “forward-looking statements” and are based on current indicators and expectations at the date of their publication. We undertake no obligation to update or revise them. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those implied in the statements.

PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS

For Existing Investors and Investment Professional Use Only.



1 Toronto St, Suite 200, Toronto, ON M5C

CLIENT SERVICES: 1.844.656.2321

416.775.3600 **Toll Free:** 1.877.860.1080

info@nextedgecapital.com

Follow us:



nextedgecapital.com